Monoclonal Antibody Imaging Of Tumors And Positron Emmis

肿瘤和正电子发射的单克隆抗体成像

• 批准号: 7212401
• 负责人: JORGE A. CARRASQUILLO
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7212401
• 关键词: HIV infections; angiogenesis; antitumor antibody; bioimaging /biomedical imaging; blood flow measurement; clinical trials; deoxyglucose; diagnosis design /evaluation; human T cell leukemia; human subject; human therapy evaluation; immunologic substance development /preparation; lymphoma; monoclonal antibody; neoplasm /cancer immunodiagnosis; neoplasm /cancer radioimmunotherapy; neoplasm /cancer radionuclide diagnosis; nuclear medicine; patient oriented research; pharmacokinetics; positron emission tomography; radiation dosage; radiation therapy dosage; radionuclide imaging /scanning; radionuclides; radiopharmacology; virus cytopathogenic effect

These antibody studies are designed to develop improved methods for detecting and treating malignancies. Our group performs preclinical evaluation of radiolabeled antibodies that appear to be promising after initial screening. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. One raidoimmunotherapy trial of Adult T-cell leukemia (ATL) has been completed. One collaborative radioimmunotherapy trial with Dr. Waldmann (PI), in which we used humanized anti-tac monoclonal antibody,in patients with non ATL lymphomas is ongoing and 3 of 4 patients with Hodgkin's have exhibited tumor response. Dr. Paik has focused his chemistry work on the chemical modification of spherical polymers (PAMAM dendrimers) as carriers of radionuclides and biological molecules including markers of angiogenesis. Various protocols using [F-18] FDG in PET and [O-15] water for tumor detection, followup, and blood flow measurements are ongoing with NCI. We continue work using FDG as a surrogate marker of resposne and disease status in a variety of malignacy. We continue to build on prior studies and are utilizing fluorodeoxyglucose PET in attemps to localize sites of activated lymphomcytes. We continue to evaluate the ability of FDG-PET to differentiate between patients with benign versus lymphomatous adenopathy in the setting of autoimmune lymphoprolifertive syndrome versus. We are collaborating within the Imaging science program and NIAID in evalauting new tracer to evaluate the pathogenesis of HIV infection in vitro.

这些抗体研究旨在开发用于检测和治疗恶性肿瘤的改进方法。我们的小组进行放射性标记抗体的临床前评价，初步筛选后似乎是有希望的。本课题组进行了药代动力学和剂量学的临床试验。一项成人T细胞白血病（ATL）的放射免疫治疗试验已经完成。与Waldmann博士（PI）合作的一项放射免疫治疗试验正在进行中，其中我们使用人源化抗tac单克隆抗体治疗非ATL淋巴瘤患者，4例霍奇金淋巴瘤患者中有3例表现出肿瘤缓解。Paik博士的化学工作主要集中在球形聚合物（PAMAM树枝状聚合物）的化学修饰上，作为放射性核素和生物分子（包括血管生成标记物）的载体。使用PET中的[F-18] FDG和[O-15]水进行肿瘤检测、随访和血流测量的各种方案正在与NCI一起进行。我们将继续使用FDG作为各种疾病的缓解和疾病状态的替代标志物。我们继续建立在以前的研究，并正在利用氟脱氧葡萄糖PET在pneumonia定位网站的活化淋巴细胞。我们将继续评估FDG-PET在自身免疫性淋巴增生综合征和淋巴结转移中区分良性和淋巴瘤性腺病的能力。我们正在与成像科学计划和NIAID合作评估新的示踪剂，以评估体外HIV感染的发病机制。